ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that Douglas E.
Williams, Ph.D., President and Chief Scientific Officer, will provide an
update on company activities at the Natixis Bleichroeder Second Annual
Hidden Gems Conference in New York on Monday, October 13, 2008 at 2:00
p.m. Eastern Daylight Time.
A live webcast of the presentation can be accessed by going to: www.zymogenetics.com.
The webcast will be archived for 30 days.
About ZymoGenetics
ZymoGenetics discovers and develops novel protein therapeutics that are
based on the Company’s research and biological
insights into key disease pathways. The Company developed and markets
RECOTHROM® Thrombin,
topical (Recombinant), which is the first recombinant, plasma-free
thrombin. Other product candidates span a wide array of clinical
opportunities that include cancer, autoimmune and viral diseases.
ZymoGenetics intends to commercialize product candidates through
internal development, collaborations with partners, and out-licensing of
patents from its extensive patent portfolio. For further information,
visit www.zymogenetics.com.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on the current intent and
expectations of the management of ZymoGenetics. These statements
are not guarantees of future actions and involve uncertainties that are
difficult to predict. Except as required by law, ZymoGenetics undertakes
no obligation to update any forward-looking or other statements in this
press release, whether as a result of new information, future events or
otherwise.
ZymoGenetics, Inc.
Susan W. Specht, MBA, 206-442-6592
Director,
Corporate Communications
or
Michael Fitzpatrick, 206-442-6702
Associate
Director, Corporate Communications
